NYSE · LLY
Eli Lilly and Company
$1,422.50+$48.80 (+3.55%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 1.88% below the high.
Loading market information…
NASDAQ · VIGL · USD
Stock price, earnings
Quote as of Aug 5, 2025, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Vigil Neuroscience, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.62% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Vigil Neuroscience, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Vigil Neuroscience, Inc., founded in 2020 and headquartered in Cambridge, Massachusetts, is a biotechnology company concentrating on microglia to develop transformative treatments for neurodegenerative diseases. The firm aims to provide disease-altering therapies for patients, their families, and caregivers affected by both rare and widespread neurological disorders. The company's primary experimental therapy is VGL101, a fully human monoclonal antibody (mAb). This compound is engineered to activate the triggering receptor expressed on myeloid cells 2 (TREM2) and is currently in Phase I clinical trials. VGL101 is being investigated for its potential in treating adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), cerebral adrenoleukodystrophy, and Alzheimer's disease. Furthermore, Vigil Neuroscience is also advancing an orally administered small molecule designed to act as a TREM2 agonist. This alternative therapeutic approach targets common neurodegenerative conditions associated with impaired microglial function.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:36 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Nov 7, 2023 |
| -$0.53+7.02% vs estimate |
| $0.00 |
THE ANALYST VIEW
7 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,422.50+$48.80 (+3.55%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 1.88% below the high.
$38.52-$0.40 (-1.02%)
Edgewise Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 20.6% below the high.
$33.59+$0.01 (+0.03%)
Pharvaris N.V.’s quoted price sits in the upper half of its reported 52-week range, 22.34% below the high.
$20.66-$0.83 (-3.84%)
Tyra Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 49.19% below the high.
$4.37-$0.03 (-0.68%)
Entrada Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 73.43% below the high.
$2.25-$0.17 (-6.85%)
PepGen Inc.’s quoted price sits in the lower half of its reported 52-week range, 71.22% below the high.
$15.57+$0.16 (+1.04%)
Rallybio Corporation’s quoted price sits in the upper half of its reported 52-week range, 11.4% below the high.
$8.05+$0.28 (+3.6%)
Xilio Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 34.66% below the high.
